ホームMCPワークベンチSkills
ホームワークベンチ通知マイページ
llms.txt · MCPガイドプライバシーポリシー · 利用規約 · サポートv1.8.3
  1. ホーム
  2. /化合物

トリメブチン

Trimebutine

HCID 5573
反応を作成
印刷

データを補完しています。しばらくしてからページを更新すると最新の内容を表示できます

基本情報概要名称と識別子物性安全と法規制化学と産業関連反応化合物ノート
部分構造検索類似構造を探す

基本情報

CAS
39133-31-8
標準SMILES
CCC(COC(=O)c1cc(OC)c(OC)c(OC)c1)(c1ccccc1)N(C)C
InChIKey
LORDFXWUHHSAQU-UHFFFAOYSA-N
分子式
C22H29NO5
平均分子量
387.5 g/mol
単同位体質量
387.20457303

概要

3,4,5-trimethoxybenzoic acid [2-(dimethylamino)-2-phenylbutyl] ester is a trihydroxybenzoic acid.

名称と識別子

優先名称
Trimebutine
IUPAC
[2-(dimethylamino)-2-phenylbutyl] 3,4,5-trimethoxybenzoate
現地名
トリメブチン
英語名
Trimebutine
分子式
C22H29NO5
分子量
387.47

名称と別名

trimebutine39133-31-8TrimebutinumTrimebutina2-(Dimethylamino)-2-phenylbutyl 3,4,5-trimethoxybenzoateTransacalmModulon2-Dimethylamino-2-phenylbutyl 3,4,5-trimethoxybenzoatQZ1OJ92E5RMaleate, TrimebutineMaleate Salt, TrimebutineSalt, Trimebutine Maleate
名称をさらに表示
トリメブチン3,4,5-トリメトキシ安息香酸2-ジメチルアミノ-2-フェニルブチル3,4,5-トリメトキシ安息香酸2-(ジメチルアミノ)-2-フェニルブチルトリメブチン BASE3,4,5-TRIMETHOXYBENZOIC ACID 2-[DIMETHYLAMINO]-2-PHENYLBUTYL ESTERMebutinTRIMEBUTINAPI Trimebutinetrimebutine free baseTrimebutine USP/EP/BPTrimebutine hydrochlorideTRIMEBUTINE 0.787% GRANULESCholesterol hemisuccinate Tris salt
DTXSID4023707(+-)-TrimebutineRefChem:389346DTXCID503707A03AA05TM906254-309-2Benzoic acid, 3,4,5-trimethoxy-, 2-(dimethylamino)-2-phenylbutyl ester

データベース識別子

物性

構造計算による物性補完中

XLogP
4
極性表面積
57.2 Ų
水素結合供与体数
0
水素結合受容体数
6
回転可能結合数
10
重原子数
28
形式電荷
0
複雑度
466

実験および物理化学的性質

DrugsPharmaceutical
SolubilityInsoluble
Endocrine DisruptorsPotential endocrine disrupting compound
Melting Point78-82
Collision Cross Section193.19 Ų [M+K]+ [CCS Type: TW; Method: calibrated with polyalanine and drug standards]

物理化学的性質

融点
78 · 78-80°C
沸点
513.42 °C · 513.42°C (rough estimate)
比重(密度)
1.1998 · 1.1998 (rough estimate)
屈折率
1.5614 · 1.5614 (estimate)
貯蔵温度
2 · 2-8°C
溶解性
クロロホルム(微量)、酢酸エチル(微量)、メタノール(微量)
外見
Solid
酸解離定数(Pka)
7.29 · 7.29±0.50(Predicted)
色
ホワイトからオフホワイト
水溶解度
10 g/L · 10g/L

安全と法規制

安全情報は参考情報です。供給元の安全データシート(SDS)、適用法令、専門家による評価に代わるものではありません。

GHS分類

GHS Classification · 5 件

This chemical does not meet GHS hazard criteria for 61.5% (8 of 13) of all reports.

Warning

H302 (23.1%): Harmful if swallowed [Warning Acute toxicity, oral]

P261, P264, P270, P271, P273, P280, P301+P317, P302+P352, P304+P340, P317, P321, P330, P362+P364, and P501 (click each P-code to see the statement)

Aggregated GHS information provided per 13 reports by companies from 5 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.

危険有害性情報

Regulatory Information · 2 件

Chemical: Benzoic acid, 3,4,5-trimethoxy-, 2-(dimethylamino)-2-phenylbutyl ester

REACH registered substance: Trimebutine (EC: 254-309-2)

Hazard Classes and CategoriesAcute Tox. 4 (23.1%)

毒性情報

Drug Induced Liver Injury · 4 件

Drug-Induced Liver Injury Severity and Toxicity (DILIst)

Trimebutine

DILI Positive

DOI:10.1016/j.drudis.2019.09.022

安全データ

wgk
3
hs_code
2922.19.0900
ストレージクラス
11 - Combustible Solids

化学と産業

薬理情報

ATC Code · 2 件

A - Alimentary tract and metabolism

QA - Alimentary tract and metabolism

Protein BindingProtein binding is minimal with 5% in vivo and in vitro to serum albumin.
Pharmacodynamics · 1 件

Trimebutine is a spasmolytic agent that acts directly on smooth muscle to modulate gastric motility. It shows a "dual function" that stimulates or inhibits spontaneous contractions depending on the concentration and prior contractile activity in the preparation. Targeting ion conductance that regulates GI motility, trimebutine inhibits the inward calcium currents and calcium-dependent potassium currents in a concentration-dependent manner. At lower concentrations (1-10uM), trimebutine depolarizes the resting membrane potential without affecting the amplitude of contractions, which is thought to be mediated by inhibition of outward potassium currents. It is also shown to activate T-type Ca2+ channel and increase gastric emptying, intestinal and colonic contractility. At higher concentrations (100-300uM), reduced amplitude of spontaneous contractions and action potentials is thought to be mediated by inhibition of L-type Ca2+ channels and inward calcium current. Trimebutine mediates a local anesthetic action by acting as a weak agonist at mu opioid receptors.

Mechanism of Action · 1 件

At high concentrations, trimebutine is shown to inhibit the extracellular Ca2+ influx in the smooth muscle cells through voltage dependent L-type Ca2+ channels and further Ca2+ release from intracellular Ca2+ stores. Trimebutine is suggested to bind to the inactivated state of the calcium channel with high affinity. Reduced calcium influx attenuates membrane depolarization and decrease colon peristalsis. It also inhibits outward K+ currents in response to membrane depolarization of the GI smooth muscle cells at resting conditions through inhibition of delayed rectifier K+ channels and Ca2+ dependent K+ channels, which results in induced muscle contractions. Trimebutine binds to mu opioid receptors with more selectivity compared to delta or kappa opioid receptors but with lower affinity than their natural ligands. Its metabolites (N-monodesmethyl-trimebutine or nor-trimebutine), are also shown to bind to opoid receptors on brain membranes and myenteric synaptosomes.

関連反応

2 件
反応記録を作成
HRID 1445952 の反応式
HRID 1445952反応物として
HRID 1879077 の反応式
HRID 1879077反応物として

化合物ノート

このページの内容基本情報概要名称と識別子物性安全と法規制化学と産業関連反応化合物ノート
CAS
39133-31-8、58997-89-0、58997-90-3
PubChem CID
5573
DTXSID
DTXSID4023707
ChEMBL
CHEMBL190044
ChEBI
CHEBI:94458
UNII
9RKX7S7WFY、QZ1OJ92E5R、U4UUZ24TRB
EC Number
254-309-2、261-548-6
Nikkaji
J15.812G、J304.096H、J304.097F
Merck
14 · 14,9699
主な用途
法医学と毒物学医薬品(低分子化合物)獣医
InChI
1S/C22H29NO5/c1-7-22(23(2)3,17-11-9-8-10-12-17)15-28-21(24)16-13-18(25-4)20(27-6)19(14-16)26-5/h8-14H,7,15H2,1-6H3
InChIKey
LORDFXWUHHSAQU-UHFFFAOYSA-N
SMILES
CCC(COC(=O)c1cc(OC)c(OC)c(OC)c1)(N(C)C)c2ccccc2
CAS データベース
39133 · 39133-31-8(CAS DataBase Reference)
Biological Half-LifeThe elimination half life is approximately 1 hour following a single oral dose of 2mg/kg, and 2.77 hours following a single oral dose 200 mg.
Metabolism/Metabolites · 1 件

Trimebutine undergoes extensive hepatic first-pass metabolism. Nortrimebutine, or N-monodesmethyltrimebutine, is the main metabolite that retains pharmacological activity on the colon. This metabolite can undergo second N-demethylation to form N-didesmethyltrimebutine. Other main urinary metabolites (2-amino, 2-methylamino or 2-dimethylamino-2-phenylbutan-1-ol) can be formed via hydrolysis of the ester bond of desmethylated metabolites or initial hydrolysis of the ester bond of trimebutine followed by sequential N-demethylation. Trimebutine is also prone to sulphate and/or glucuronic acid conjugation.

MeSH Pharmacological Classification · 2 件

Drugs used for their effects on the gastrointestinal system, as to control gastric acidity, regulate gastrointestinal motility and water flow, and improve digestion.

Agents that inhibit the actions of the parasympathetic nervous system. The major group of drugs used therapeutically for this purpose is the MUSCARINIC ANTAGONISTS.

Absorption, Distribution and Excretion · 3 件

The free base form or salt form of trimebutine are rapidly absorbed after oral administration, with the peak plasma concentration reached after 1 hour of ingestion. The time to reach peak plasma concentration following a single oral dose of 200mg trimebutine is 0.80 hours.

Renal elimination is predominant while excretion into feces is also observed (5-12%). About 94% of an oral dose of trimebutine is eliminated by the kidneys in the form of various metabolites and less than 2.4% of total ingested drug is recovered as unchanged parent drug in the urine.

Trimebutine is most likely to be accumulated in the stomach and the intestinal walls in highest concentrations. The fetal transfer is reported to be low.

応用分野

用途オピオイド作動薬消化管運動調整

使用Trimebutine is an agonist of peripheral mu, kappa and delta opiate receptors, used as spasmolytic agent for treatment of both acute and chronic abdominal pain.

上流・下流製品情報

上流原料

2-アミノ-2-フェニル酪酸